JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-11-08: Form 8-K; Period of report 2012-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-10-25: Form 8-K; Period of report 2012-10-24; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2012-10-05: Form 8-K; Period of report 2012-10-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-09-05: Form 8-K; Period of report 2012-09-05; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-11-08 | 8-K | 2012-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Third Quarter 2012 Financial Results” (the “Press Release”). | a2012q3earningsrelease.htm |
| 2012-10-25 | 8-K | 2012-10-24 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On October 24, 2012, Columbia Laboratories, Inc. (the “Company”) received a letter from the Nasdaq Stock Market indicating that for 30 consecutive business days the Company's common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5450(a)(1). | a20128k24oct.htm |
| 2012-10-05 | 8-K | 2012-10-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 4, 2012, George W. Creasy, MD, resigned from his position as vice president, clinical research, of Columbia Laboratories, Inc. The resignation is effective October 18, 2012. | georgecreasyresignation.htm |
| 2012-09-05 | 8-K | 2012-09-05 | 7.01 Regulation FD Disclosure | 7.01 Frank C. Condella, Jr., president and chief executive officer of Columbia Laboratories, Inc. (the “Company”), and Lawrence A. Gyenes, the Company's senior vice president and chief financial officer, will present to various investors beginning September 5, 2012. | investorpresentation.htm |
| 2012-08-08 | 8-K | 2012-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Second Quarter 2012 Financial Results” (the “Press Release”). | a2012q28-kearningsrelease.htm |
| 2012-07-26 | 8-K | 2012-07-24 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | scientelle8k.htm |
| 2012-06-11 | 8-K | 2012-06-07 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 The 2012 Annual Meeting of Stockholders (the “Annual Meeting”) of Columbia Laboratories, Inc. (the “Company”) was held on June 7, 2012. 8.01 On June 7, 2012, the Board of Directors of the Company took the following actions relating to the organization of the Board and compensation of Directors. | a2012annualmtgvote6712.htm |
| 2012-05-04 | 8-K | 2012-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports First Quarter 2012 Financial Results” (the “Press Release”). | a8-k2012q1pressrelease.htm |
| 2012-03-13 | 8-K | 2012-03-13 | 7.01 Regulation FD Disclosure | 7.01 On March 13, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Hires Cowen and Company to Assist in Evaluating Potential Strategic Transactions” (the “Press Release”). | form8-kcowen.htm |
| 2012-03-08 | 8-K | 2012-03-08 | 2.02 Results of Operations and Financial Condition | 2.02 On March 8, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Fourth Quarter and Year End 2011 Financial Results” (the “Press Release”). | a2012form8-kq4earnings.htm |
| 2012-03-06 | 8-K | 2012-03-06 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 6, 2012, Columbia Laboratories, Inc. (the “Company”) received a letter from the Nasdaq Stock Market indicating that for 30 consecutive business days the Company's common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5450(a)(1). | secform8-knasdaqminbid.htm |
| 2012-03-05 | 8-K | 2012-03-01 | 7.01 Regulation FD Disclosure | 7.01 On March 1, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Announces 42% Workforce Reduction” (the “Press Release”). | form8-krif.htm |
| 2012-02-27 | 8-K | 2012-02-27 | 7.01 Regulation FD Disclosure | 7.01 On February 27, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%” (the “Press Release”). | form8-kfddisclosure.htm |
| 2012-02-15 | 8-K | 2012-02-10 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events | 1.01 A description of the Waiver Agreement is set forth under Item 2.01 of this Current Report on Form 8-K and is incorporated by reference into this item. 2.01 On February 10, 2012, Columbia Laboratories, Inc. (the “Company”) and Coventry Acquisition, LLC (the “Buyer”), a subsidiary of Watson Pharmaceuticals, Inc. (“Watson”), completed the second closing of the previously announced Purchase and Collaboration Agreement, dated as of March 3, 2010 (the “Purchase Agreement”), among the Company, the Buyer and Watson. 8.01 On February 13, 2012, the Company issued a press release entitled, “Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals” (the “Press Release”). | form8kdated02102012.htm |
| 2012-01-23 | 8-K | 2012-01-20 | 7.01 Regulation FD Disclosure | 7.01 On January 20, 2012, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length” (the “Press Release”). | a2012form8-k.htm |